- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02101749
Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group.
Comparative Immune Response of Intradermal and Intramuscular Preparations of
This is a prospective, Open label randomized study. A total of 220 adults aged ≥ 60 years will be enrolled and randomized to one of 2 study arms:
- Seasonal inactivated intradermal influenza vaccine (15 μg HA (hemagglutinin) per strain/ 0.1 ml dose) (group A - 110 participants)
- Seasonal inactivated intramuscular influenza vaccine (15 μg HA per strain/ 0.5 ml dose) (group B - 110 participants) Groups A and B will receive the vaccine at day 1. Total follow up period is 60 days.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The consent form will be reviewed and signed by the participant prior to any study-related procedures.
Potential study participants will be assessed based on inclusion and exclusion criteria. Screening procedures, which include taking medical history, vital signs, random blood for dextrostix and vaccination will be performed on day 1.
A total of 220 participants will be randomized into 2 study arms, of which each group of 110 vaccinees will receive either seasonal intradermal influenza vaccine [group A] or seasonal intramuscular influenza vaccine [group B]. The randomization route of vaccination will be kept in concealed envelope at the study site. It will be open after subject signed informed consent form and all inclusion exclusion criteria met for enrollment. Groups A and B will receive the vaccine at day 1. Clinical activities for groups A and B during each visit (total of 5 visits). Blood will be drawn and assayed (for baseline assessment) using HAI (hemagglutination inhibition assay) to the three influenza strains.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
Bangkok, Thailand, 10400
- Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University,
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
- Male or female aged ≥ 60 years
- Healthy and/or medically stable with controlled chronic medical conditions (e.g. diabetes mellitus, hypertension ) able to help oneself
Exclusion criteria:
- Known history of systemic hypersensitivity to egg or chicken proteins or any of the vaccine components
- Influenza infection within the past 3 months
- History of Guillain Barre Syndrome (GBS) or brachial neuritis within 6 weeks of previous influenza vaccination
- Treatment with immunosuppressive or other immune-modifying drugs or cancer therapy within the past 6 months
- Any concomitant medication with aspirin
- Participation in other intervention study
- Incapacity to provide fully informed consent or be attentive to follow-up observations resulting from cognitive impairment, abuse of alcohol or drug addiction
- Random blood for Dextrostix more than 200 mg/dL
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: trivalent inactivated influenza (INTANZA)
Intradermal injection
|
intradermal or intramuscular injection in the deltoid area.
|
Aktiv komparator: trivalent inactivated influenza (VAXIGRIP)
Intramuscle injection
|
intradermal or intramuscular injection in the deltoid area.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Immunological end point
Tidsram: with in 60 days post vaccination
|
Vaccine is able to induce a 4-fold rise of Hemagglutination inhibition antibodies 70% of vaccinees within 60 days after vaccination (according to EMA (European Medicines Agency) and CBER (Center for Biologics Evaluation and Research) guidelines)
|
with in 60 days post vaccination
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
To assess safety
Tidsram: 60 Days
|
To assess safety of the following trivalent inactivated seasonal influenza vaccine in the older age group
|
60 Days
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Assess other related immune response
Tidsram: 60 days
|
Exploratory objective to assess other related immune response (e.g.
anti-neuraminidase)
|
60 days
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Punnee Pitisuttithum, MD, Mahidol University
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Elderly Flu vaccine
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Influensa, människa
-
USDA, Western Human Nutrition Research CenterUniversity of Copenhagen; Bill and Melinda Gates Foundation; International... och andra samarbetspartnersRekryteringHuman Milk Nutrient ReferensvärdenDanmark, Bangladesh, Brasilien, Gambia
-
Instituto Valenciano de Infertilidad, IVI VALENCIAIgenomixAvslutadGenomisk Human Endometrial Expression ProfileSpanien
-
Washington University School of MedicineMerck Sharp & Dohme LLCIndragenHuman T-cell Leukemi Virus Typ 1 Infektion
-
Filip Krag KnopUniversity of CopenhagenAvslutadAtt bedöma effekten av gallsyror på utsöndring av human glukagon-liknande peptid-1Danmark
-
HutchmedAktiv, inte rekryterandeImumun Trombocytopeni (ITP) Human Mass BalanceKina
-
Medigen Vaccine Biologics Corp.Avslutad
-
Medigen Vaccine Biologics Corp.Avslutad
-
Jinling Hospital, ChinaOkändCrohns sjukdom | Metylering | Illumina Human Methylation 850k BeadChipKina
-
Qingdao Central HospitalAvslutadHuman epidermal tillväxtfaktor 2 negativt bröstkarcinomKina
-
Herlev HospitalAvslutadHuman endotoxemiDanmark
Kliniska prövningar på trivalent inactivated influenza
-
SeqirusAvslutadInfluensa, människaFörenta staterna
-
SeqirusAvslutadInfluensaKalkon, Filippinerna, Thailand, Malaysia, Litauen, Colombia, Tjeckien, Estland, Bulgarien, Lettland, Polen, Rumänien
-
SeqirusNovartis VaccinesAvslutad
-
PATHBill and Melinda Gates Foundation; Children's Hospital Medical Center,... och andra samarbetspartnersAvslutadRotavirusvaccinSydafrika
-
SeqirusNovartis VaccinesAvslutadInfluensaFörenta staterna, Finland, Filippinerna, Thailand
-
Center for Disease Prevention and Control of Beijing...Avslutad
-
SanofiAvslutadInfluensa | MyxovirusinfektionFörenta staterna
-
Green Cross CorporationAvslutad
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)AvslutadLeukemi | InfektionFörenta staterna